Henrik Østergaard, PhD, MSc, serves as Scientific Vice President at Hemab. He has 18 years of experience within early biopharmaceutical drug discovery and development, most recently in the role as Scientific Director at Novo Nordisk A/S. With a particular focus on early innovation, protein engineering, and enzymology, Henrik has led several drug development projects within the hemophilia space, of which Refixia®is currently on the market. He is the author of numerous scientific publications and an inventor of patents covering new technologies and therapeutic molecules. He earned an MSc and a PhD from the Technical University of Denmark.